COVID; COVID; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient’s relevant medical history included: “Small fiber neuropathy” (unspecified if ongoing); “adrenergic dysautonomia” (unspecified if ongoing); “POTS” (unspecified if ongoing); “ataxia” (unspecified if ongoing); “downbeating nystagmus” (unspecified if ongoing); “superventicular tachycardia” (unspecified if ongoing); “severe dysmotility issues” (unspecified if ongoing); “left atrial inflammation x4” (unspecified if ongoing); “ocular rosacea” (unspecified if ongoing); “blephiritis” (unspecified if ongoing); “polyneuropathy” (unspecified if ongoing); “immune deficiency” (unspecified if ongoing); “macrocytosis without anemia” (unspecified if ongoing); “elevated liver enzymes” (unspecified if ongoing), notes: gone; “gone-acute fatty liver- gone” (unspecified if ongoing), notes: gone; “Igg3 subclass deficiency” (unspecified if ongoing); “left arm swelled to wrist and halfway down back” (unspecified if ongoing); “Still hurts” (unspecified if ongoing); severe dysmotility issues; b cells tanking wbc. The patient’s concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome “unknown” and all described as “COVID”. Clinical course: First shot. Not safe or effective. Still got Covid a year and a half later. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.